Agios Announces the Randomized Phase 3 ClarIDHy Trial of TIBSOVO® (ivosidenib) Achieved its Primary Endpoint in Previously Treated IDH1 Mutant Cholangiocarcinoma Patients

World News: . []

CAMBRIDGE Mass May 15 2019 GLOBE NEWSWIRE -- Agios Pharmaceuticals Inc NASDAQAGIO a LINK  in the field of cellular metabolism to treat cancer and rare LINK  diseases today announced that the LINK  Phase 3 ClarIDHy trial of TIBSOVO (ivosi...

More news and information about Agios Pharmaceuticals, Inc.

Published By:

Globe Newswire: 21:01 GMT Wednesday 15th May 2019

Published: .

Search for other references to "agios" on SPi News


Share

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
 
Privacy Policy | Terms and Conditions | Contact Us